Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health unit Opella to a US investment fund, after providing the French government ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. This newsletter was penned in ...

Sanofi in talks to sell 50% stake in Opella for €15 billion ($16.4 billion). Goldman Sachs and Morgan Stanley arrange €6 billion in debt financing for buyers. According to the Bloomberg report ...

On Friday, Sanofi SA (NASDAQ:SNY) said it is negotiating with Clayton Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business. According to ...

Instead, it risks becoming a political football. Sanofi SA nudged the auction for its consumer health business nearer to consummation on Friday, agreeing exclusive talks to sell a “50% ...

Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said ...

The French government is looking at options including state-owned investment bank BPIfrance taking a stake in the consumer health business that Sanofi is in talks to sell to US buyout firm Clayton ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...